The Crescentic Implication of Renal Outcomes in Proliferative Lupus Nephritis

REFERENCES

1. 1.↵
   1. Lorenz G,
   2. Desai J,
   3. Anders HJ

   . Lupus nephritis: update on mechanisms of systemic autoimmunity and kidney immunopathology. Curr Opin Nephrol Hypertens 2014;23:211–7.

   OpenUrlCrossRef
2. 2.↵
   1. Li M,
   2. Zhang W,
   3. Leng X,
   4. Li Z,
   5. Ye Z,
   6. Li C,
   7. et al.

   Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Lupus 2013;22:1192–9.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Weening JJ,
   2. D’Agati VD,
   3. Schwartz MM,
   4. Seshan SV,
   5. Alpers CE,
   6. Appel GB,
   7. et al.

   The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241–50.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Schwartz MM,
   2. Korbet SM,
   3. Lewis EJ;
   4. Collaborative Study Group

   . The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant 2008;23:1298–306.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Zhang W,
   2. Yuan M,
   3. Hong L,
   4. Zhou Q,
   5. Chen W,
   6. Yang S,
   7. et al.

   Clinical outcomes of lupus nephritis patients with different proportions of crescents. Lupus 2016;25:1532–41.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Austin HA 3rd,
   2. Muenz LR,
   3. Joyce KM,
   4. Antonovych TT,
   5. Balow JE

   . Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689–95.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Ginzler EM,
   2. Dooley MA,
   3. Aranow C,
   4. Kim MY,
   5. Buyon J,
   6. Merrill JT,
   7. et al.

   Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219–28.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Wang J,
   2. Hu W,
   3. Xie H,
   4. Zhang H,
   5. Chen H,
   6. Zeng C,
   7. et al.

   Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007;16:707–12.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Yu F,
   2. Tan Y,
   3. Liu G,
   4. Wang SX,
   5. Zou WZ,
   6. Zhao MH

   . Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 2009;76:307–17.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Chen S,
    2. Tang Z,
    3. Zhang Y,
    4. Liu Z,
    5. Zhang H,
    6. Hu W,
    7. et al.

    Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis. Am J Nephrol 2013;38:445–52.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Tan Y,
    2. Song D,
    3. Wu LH,
    4. Yu F,
    5. Zhao MH

    . Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis. BMC Nephrol 2013;14:63.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Alsuwaida A,
    2. Husain S,
    3. Al Ghonaim M,
    4. Aloudah N,
    5. Ullah A,
    6. Kfoury H

    . Prognostic significance of C1q deposition in serial biopsies for predicating the long-term outcome in patients with proliferative lupus nephritis. Saudi J Kidney Dis Transpl 2016;27:305–11.

    OpenUrl
13. 13.↵
    1. Wu LH,
    2. Yu F,
    3. Tan Y,
    4. Qu Z,
    5. Chen MH,
    6. Wang SX,
    7. et al.

    Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 2013;83:715–23.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Yu F,
    2. Wu LH,
    3. Tan Y,
    4. Li LH,
    5. Wang CL,
    6. Wang WK,
    7. et al.

    Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 2010;77:820–9.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Hill GS,
    2. Delahousse M,
    3. Nochy D,
    4. Tomkiewicz E,
    5. Remy P,
    6. Mignon F,
    7. et al.

    A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000;58:1160–73.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Anders HJ,
    2. Banas B,
    3. Schlondorff D

    . Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 2004;15:854–67.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Anders HJ,
    2. Vielhauer V,
    3. Eis V,
    4. Linde Y,
    5. Kretzler M,
    6. Perez de Lema G,
    7. et al.

    Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. Faseb J 2004;18:534–6.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Benigni A,
    2. Caroli C,
    3. Longaretti L,
    4. Gagliardini E,
    5. Zoja C,
    6. Galbusera M,
    7. et al.

    Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum 2007;56:1569–78.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Shankland SJ,
    2. Smeets B,
    3. Pippin JW,
    4. Moeller MJ

    . The emergence of the glomerular parietal epithelial cell. Nat Rev Nephrol 2014;10:158–73.

    OpenUrlCrossRefPubMed